Short-Acting B2 Agonists Global Market Report 2025

The short-acting B2 agonist market size has grown steadily in recent years. It will grow from $4.25 billion in 2024 to $4.44 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth during the historic period can be attributed to an increase in the pediatric asthma population, a rising prevalence of environmental allergens, growing urbanization and pollution levels, a stronger focus on preventing asthma exacerbations, and an expanding number of research and development initiatives.

The short-acting B2 agonist market size is expected to see steady growth in the next few years. It will grow to $5.29 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth during the forecast period can be attributed to the rising prevalence of asthma and chronic obstructive pulmonary disease (COPD), increasing awareness about asthma management, growing government initiatives for asthma and COPD treatment, rising global healthcare expenditure, and an expanding geriatric population. Key trends expected during this period include advancements in inhaler technologies, a growing market for personalized asthma treatments, the development of more convenient drug delivery systems, technological innovations in nebulizers for home use, and improvements in drug formulations for enhanced efficacy.

The growing prevalence of chronic obstructive pulmonary disease (COPD) is expected to fuel the expansion of the short-acting B2 agonists market. COPD is a long-term lung disease that results in breathing difficulties and reduced airflow, primarily caused by prolonged exposure to harmful gases or cigarette smoke. The increase in COPD cases can be attributed to rising exposure to air pollution, as long-term inhalation of pollutants such as particulate matter and toxic gases can damage lung tissue and accelerate the disease’s progression. Short-acting β2-agonists (SABAs) are commonly used in COPD management to quickly relieve symptoms such as shortness of breath by relaxing airway muscles. These medications are often used as rescue treatments during flare-ups but are not intended for long-term management. For example, in July 2024, the Australian Institute of Health and Welfare reported that COPD was responsible for 7,691 deaths in 2022, or 29.6 per 100,000 population, accounting for 4% of all fatalities in the country. As COPD cases continue to rise, the demand for short-acting B2 agonists is expected to grow.

Key companies operating in the short-acting B2 agonists market are focusing on the development of advanced products such as pressurized metered-dose inhalers (pMDIs) to efficiently manage acute symptoms. pMDIs are portable devices that deliver a precise dose of medication to the lungs in aerosol form using a propellant-driven spray, commonly used for treating respiratory conditions such as asthma and COPD. For example, in January 2023, AstraZeneca, a UK-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Airsupra (albuterol/budesonide). This first-in-class pMDI combines albuterol, a short-acting beta2-agonist (SABA), for rapid bronchodilation, with budesonide, an inhaled corticosteroid (ICS), to reduce inflammation. Approved for the treatment and prevention of bronchoconstriction in adults with asthma, Airsupra also helps reduce the risk of exacerbations, offering a comprehensive approach to asthma management.

In April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based producer of short-acting B2 agonists, entered into a partnership with Launch Therapeutics Inc. to accelerate the development of Teva's ICS clinical research program-SABA (TEV-'248). Through this collaboration, Teva aims to fast-track the development and commercialization of its dual-action asthma rescue inhaler, providing a more effective treatment option for both adult and pediatric asthma patients. Launch Therapeutics Inc. is a U.S.-based clinical development company.

Major players in the short-acting b2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.

North America was the largest region in the short-acting B2 agonists market in 2024. The regions covered in short-acting beta-2 agonists report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the short-acting beta-2 agonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Short-acting beta-2 agonists are a class of medications commonly used for quick relief of symptoms related to asthma and other respiratory conditions. These drugs work by stimulating beta-2 adrenergic receptors in the smooth muscles of the airways, resulting in rapid bronchodilation, or the relaxation of muscles around the airways.

The main types of short-acting beta-2 agonists include albuterol, levalbuterol, metaproterenol, and others. Albuterol is a widely used short-acting beta-2 agonist that provides quick relief from bronchospasm by relaxing airway muscles. It is used for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and exercise-induced bronchospasm. Albuterol can be administered through inhalation, oral, or injection routes and is used by various end users, including hospitals, clinics, and home healthcare settings.

The short-acting b2 agonists market research report is one of a series of new reports that provides short-acting b2 agonists market statistics, including short-acting b2 agonists industry global market size, regional shares, competitors with a short-acting b2 agonists market share, detailed short-acting b2 agonists market segments, market trends and opportunities, and any further data you may need to thrive in the short-acting b2 agonists industry. This short-acting b2 agonists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The short-acting beta-2 agonists market consists of sales of nebulizer solutions, combination inhalers, respiratory monitoring devices, spacers and holding chambers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.